ES2175028T3 - Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva. - Google Patents
Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva.Info
- Publication number
- ES2175028T3 ES2175028T3 ES96203571T ES96203571T ES2175028T3 ES 2175028 T3 ES2175028 T3 ES 2175028T3 ES 96203571 T ES96203571 T ES 96203571T ES 96203571 T ES96203571 T ES 96203571T ES 2175028 T3 ES2175028 T3 ES 2175028T3
- Authority
- ES
- Spain
- Prior art keywords
- paclitaxel
- beta
- prodrugs
- prodrug
- profarmacos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C263/00—Preparation of derivatives of isocyanic acid
- C07C263/12—Preparation of derivatives of isocyanic acid from or via nitrogen analogues of carboxylic acids, e.g. from hydroxamic acids, involving a Hofmann, Curtius or Lossen-type rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
LA INVENCION SE REFIERE A NUEVOS PROFARMACOS DE PACLITAXEL SOLUBLES EN AGUA, EN DONDE PACLITAXEL ESTA, A TRAVES DE SU FUNCIONALIDAD 2''-HIDROXILO, CONECTADO A UN GRUPO SEPARADOR SEPARABLE, EL CUAL ESTA EN CAMBIO INCORPORADO A UN GRUPO DE AZUCAR PREFERIBLEMENTE ENZIMATICAMENTE SEPARABLE. DICHOS PROFARMACOS SON RELATIVAMENTE NO TOXICOS Y PUEDEN SER UTILIZADOS EN EL TRATAMIENTO DE CANCER. PUEDEN SER SELECTIVAMENTE ACTIVADOS EN EL EMPLAZAMIENTO DEL TUMOR MEDIANTE LA ACCION DE ENZIMAS ENDOGENAS O ENZIMAS DIRIGIDAS, O MEDIANTE UN PROCEDIMIENTO NO ENZIMATICO. LA ENZIMA ES PREFERIBLEMENTE {BE}-GLUCORONIDASA, {BE}-GLUCOSIDASA O {BE}-GALACTOSIDASA. LA INVENCION TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN PROFARMACO DE PACLITAXEL COMO SE DEFINIA AQUI, EL CUAL COMPRENDE DICHO PROFARMACO CON UN PORTADOR FARMACEUTICAMENTE ACEPTABLE PARA PROPORCIONAR UNA FORMULACION SOLIDA O LIQUIDA PARA ADMINISTRACION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95203671 | 1995-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2175028T3 true ES2175028T3 (es) | 2002-11-16 |
Family
ID=8221031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96203571T Expired - Lifetime ES2175028T3 (es) | 1995-12-29 | 1996-12-17 | Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva. |
Country Status (10)
Country | Link |
---|---|
US (1) | US5760072A (es) |
EP (1) | EP0781778B1 (es) |
JP (1) | JPH09202796A (es) |
AT (1) | ATE216394T1 (es) |
CA (1) | CA2192424C (es) |
DE (1) | DE69620727T2 (es) |
DK (1) | DK0781778T3 (es) |
ES (1) | ES2175028T3 (es) |
PT (1) | PT781778E (es) |
SI (1) | SI0781778T1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997038727A1 (fr) * | 1996-04-15 | 1997-10-23 | Asahi Kasei Kogyo Kabushiki Kaisha | Composite medicamenteux |
US7357942B2 (en) * | 1997-09-26 | 2008-04-15 | Abbott Laboratories | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens |
JP4153660B2 (ja) * | 1997-10-08 | 2008-09-24 | 株式会社横浜国際バイオ研究所 | タキソイド誘導体およびその製造方法 |
US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
DE19845798A1 (de) * | 1998-09-29 | 2000-04-13 | Schering Ag | Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung |
US6043367A (en) * | 1998-09-30 | 2000-03-28 | Roffler; Steve | Proactive antitumor compounds |
US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
US20050222246A1 (en) * | 1999-04-14 | 2005-10-06 | Li Chiang J | Beta-lapachone is a broad spectrum anti-cancer agent |
AU7007001A (en) | 2000-06-22 | 2002-01-02 | Nitromed Inc | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US7070797B2 (en) * | 2000-11-07 | 2006-07-04 | Dana Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers |
US20050197405A1 (en) * | 2000-11-07 | 2005-09-08 | Li Chiang J. | Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent |
MXPA03011094A (es) * | 2001-05-31 | 2004-12-06 | Medarex Inc | Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello. |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
US6816571B2 (en) * | 2002-02-06 | 2004-11-09 | L-3 Communications Security And Detection Systems Corporation Delaware | Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner |
EP1487460A2 (en) | 2002-02-28 | 2004-12-22 | A & D Bioscience, Inc. | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof |
US20050107310A1 (en) * | 2002-03-19 | 2005-05-19 | Holick Michael F. | Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof |
WO2003086475A1 (en) * | 2002-04-12 | 2003-10-23 | A & D Bioscience, Inc. | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof |
WO2003094842A2 (en) * | 2002-05-07 | 2003-11-20 | A & D Bioscience, Inc. | Conjugates comprising central nervous system active drug |
CA2490626A1 (en) * | 2002-06-20 | 2003-12-31 | Nippon Suisan Kaisha, Ltd. | Prodrug, medicinal utilization thereof and process for producing the same |
US20050215487A1 (en) * | 2002-06-27 | 2005-09-29 | Holick Michael F | Conjugates comprising an nsaid and a sugar and uses thereof |
US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
US20050192247A1 (en) * | 2004-02-23 | 2005-09-01 | Li Chiang J. | Method of treating cancers |
WO2006042056A2 (en) * | 2004-10-08 | 2006-04-20 | The Ohio State University | Methods and compositions for enzyme-specific activation of carbohydrate-conjugated prodrugs |
FR2947455B1 (fr) | 2009-07-01 | 2014-01-03 | Centre Nat Rech Scient | La dermaseptine b2 comme inhibiteur de la croissance tumorale |
CN110227164B (zh) * | 2018-03-06 | 2021-11-23 | 江苏吉贝尔药业股份有限公司 | 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用 |
WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
EP4175966A1 (en) * | 2020-07-06 | 2023-05-10 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen | Polymeric micelles comprising glucuronide-prodrugs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
-
1996
- 1996-09-30 US US08/722,941 patent/US5760072A/en not_active Expired - Fee Related
- 1996-12-09 CA CA002192424A patent/CA2192424C/en not_active Expired - Fee Related
- 1996-12-17 AT AT96203571T patent/ATE216394T1/de not_active IP Right Cessation
- 1996-12-17 DE DE69620727T patent/DE69620727T2/de not_active Expired - Fee Related
- 1996-12-17 ES ES96203571T patent/ES2175028T3/es not_active Expired - Lifetime
- 1996-12-17 PT PT96203571T patent/PT781778E/pt unknown
- 1996-12-17 DK DK96203571T patent/DK0781778T3/da active
- 1996-12-17 EP EP96203571A patent/EP0781778B1/en not_active Expired - Lifetime
- 1996-12-17 SI SI9630480T patent/SI0781778T1/xx unknown
- 1996-12-27 JP JP8351525A patent/JPH09202796A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SI0781778T1 (en) | 2002-10-31 |
ATE216394T1 (de) | 2002-05-15 |
US5760072A (en) | 1998-06-02 |
CA2192424A1 (en) | 1997-06-30 |
JPH09202796A (ja) | 1997-08-05 |
CA2192424C (en) | 2002-01-22 |
DK0781778T3 (da) | 2002-06-17 |
DE69620727D1 (de) | 2002-05-23 |
EP0781778B1 (en) | 2002-04-17 |
DE69620727T2 (de) | 2002-08-22 |
PT781778E (pt) | 2002-08-30 |
EP0781778A1 (en) | 1997-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2175028T3 (es) | Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva. | |
CA2336815A1 (en) | Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides | |
PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
WO1998000172A3 (en) | Compositions and methods for altering the biodistribution of biological agents | |
WO2002007759A3 (en) | Clostridial toxin derivatives and methods for treating pain | |
PT1183050E (pt) | Processo para a produção de uma preparação farmacêutica injectável | |
WO1988000837A3 (en) | Advanced anticancer therapy and cytotoxic medicaments for its implementation | |
CA2211118A1 (en) | Stable lipid-comprising drug delivery complexes and methods for their production | |
UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
NZ505339A (en) | Camptothecin tetracyclic derivatives useful for inhibiting topoisomerase I and/or II pyridine intermediates thereof | |
IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
WO2000001376A3 (en) | Pharmaceutical compositions and their uses for treatment of demyelinating disorders | |
DE69533615D1 (de) | Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie | |
WO2001089571A3 (en) | Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives | |
ES2169414T3 (es) | Amino-azucar citotoxico y derivados de azucares relacionados de indolopirrolocarbazoles. | |
WO2005025512A3 (en) | Cobalamin conjugates for anti-tumor therapy | |
AU2207197A (en) | Targeted site specific drug delivery compositions and method of use | |
CA2356959A1 (en) | Water-insoluble drug delivery system | |
NO995481L (no) | Glykokonjugater av 20 (S)-camptothecin | |
TWI265027B (en) | Topical application of muscarinic analgesic drugs such as neostigmine | |
FUJII et al. | UCE1022, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from Paecilomyces | |
BR9609051A (pt) | Composição farmacêutica preparada por adição de um veículo flavorizante a um medicamento | |
JPS5515445A (en) | Introduction of amino-protecting group by microorganism | |
WO1998011919A3 (en) | Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof | |
FR2709753B1 (fr) | Nitrates organiques, leur procédé de préparation et leur application comme médicaments. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 781778 Country of ref document: ES |